Price T Rowe Associates Inc 89bio, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in 89bio, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 62,303 shares of ETNB stock, worth $591,255. This represents 0.0% of its overall portfolio holdings.
Number of Shares
62,303
Previous 47,292
31.74%
Holding current value
$591,255
Previous $370,000
22.43%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ETNB
# of Institutions
208Shares Held
158MCall Options Held
366KPut Options Held
944K-
Janus Henderson Group PLC London, X020.5MShares$194 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$189 Million3.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.3MShares$136 Million4.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.32MShares$88.4 Million2.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$68 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $441M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...